Genetic markers of endothelial dysfunction in chronic obstructive pulmonary disease
https://doi.org/10.34215/1609-1175-2024-1-48-52
Abstract
Objective. To analyze genetic markers of endothelial dysfunction in chronic obstructive pulmonary disease. Materials and methods. The study involved an examination of 285 patients with chronic obstructive pulmonary disease aged 67.12 ± 1.82, including males (73.68%) and females (26.32%). A control group consisted of 70 respondents, including 45 relatively healthy people, among whom males constituted 64.3% and females 35.7%. Polymorphisms of endothelial nitric oxide synthase NOS3 (C786T), endothelin-1 EDN1 Lys198Asn genes were examined by PCR method. Results. The cohort of COPD patients revealed a prevalence of pathological homozygous genotype 786SS NOS3 (χ2=12.84, df=1, p=0.0003). Carriage of heterozygous variant of LysAsn polymorphic marker Lys198Asn of EDN1 gene in COPD patients was detected in 32.5%. Conclusion. Manifestation of endothelial dysfunction in COPD patients is due to genotypic predisposition associated with carrying polymorphisms 786SS of NOS3 gene (OR 7.01, 95% CI 1.59-30.81) and Lys198Asn of EDN1 gene (OR 2.53, 95% CI 0.69-9.22)
About the Authors
A. Kh. Dausheva
Medical University “Reaviz” ; Samara Regional Clinical Hospital named after V.D. Seredavin (Public Funded Health Facility Samara Regional Clinical Hospital after V.D. Seredavin)
Russian Federation
Russian Federation
Aisylu Kh. Dausheva, Cand. Sci. (Med.), Associate Professor of the Department of Internal Medicine, doctor
227 Chapayevskaya street, Samara, 443001
E. G. Zarubina
Medical University “Reaviz”
Russian Federation
Russian Federation
Samara
Yu. V. Bogdanova
Samara Regional Clinical Hospital named after V.D. Seredavin (Public Funded Health Facility Samara Regional Clinical Hospital after V.D. Seredavin)
Russian Federation
Russian Federation
Samara
References
1. Chazova IE, Nevzorova VA, Ambatiello LG, Brodskaia TA, Oshchepkova EV, Belevskii AS, Zhemakova JV, Aisanov ZR, Ovcharenko SI, Chuchalin AG. Clinical practice guidelines on the diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease. Systemic Hypertension. 2020;17(3):7–34 (In Russ.). doi: 10.26442/2075082X.2020.3.200294
2. Welte ET. COPD and comorbidity. European respiratory monograph. 2013;59:228.
3. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71–86. doi: 10.1016/j.ccm.2013.10.004
4. Pare. G, Serre D, Brisson D, Anand SS, Montpetit A, Tremblay G, Engert JC, Hudson TJ, Gaudet D. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. Am. J. Hum. Genet. 2007;80:673–682. doi: 10.1086/513286
5. Dzavik V, Cotter G, Reyndolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur. Heart. J. 2007;28(9): 1109–16. doi: 10.1093/eurheartj/ehm075
6. Callahan WE, Amorosino CS. Endothelial dysfunction in pulmonary hypertension. N Engl J Med. 1992;327:117–9.
7. Liu D, Jiang Z, Dai L, Zhang X., Yan C., Han Y. Association between the – 786T>C 1polymorphism in the promoter region of endothelial nitric oxide synthase (eNOS) and risk of coronary artery disease: a systematic review and meta-analysis. Gene. 2014;545(1):175–83. doi: 10.1016/j.gene.2013.09.099
8. Nishijima T, Nakayma M, Yoshimura M, Abe K, Yamamuro M, Suzuki S, Shono M, Sugiyama S, Saito Y, Miyamoto Y, Nakao K, Yasue H, Ogawa H. The endothelial nitric oxide synthase gene – 786T/C polymorphism is a predictive factor for reattacks of coronary spasm. Pharmacogenet. Genomics. 2007;17(8):581–7. doi: 10.1097/01.fpc.0000239978.61841.1a
9. Via M, López‐Alomar A, Valveny N. Lack of association between eNOS gene polymorphisms and ischemic heart disease in the Spanish population. Am. J. Med. Genet. 2003;116(3):243–8. doi: 10.1002/ajmg.a.10805
10. Green CE, Turner AM. The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD). Respir. Res. 2017;18(1):20. doi: 10.1186/s12931-017-0505-1
11. Dzugkoev SG, Mozhaeva IV, Takoeva EA, Dzugkoeva FS, Marghieva O.I. Mechanisms of development of endothelial dysfunction and prospects correction. Fundamental research. 2014;4:198–204. URL: https://fundamental-research.ru/ru/article/view?id=33696
12. Davignon J Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:27–32. doi: 10.1161/01.CIR.0000131515.03336.f8
13. Hynynen MM, Khalil RA. The vascular endothelin system in hypertension–recent patents and discoveries. Recent Pat Cardiovasc Drug Discov. 2006;1(1):95–108. doi: 10.2174/157489006775244263
14. Polverino F, Bartolome R. Celli, Caroline A. Owen. COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? Pulm Circ. 2018;8(1):2045894018758528. doi: 10.1177/2045894018758528
15. Almazov VA, Berkovich OA, Sitnikova MYu, Volkova EV, Bazhenova EA, Alugishvili MZ, Tolstova IA, Khmelnitskaya KA, Shlyakhto EV. Endothelial disfunction in patients with ishemic heart disease. Relation to the age of on set symptoms. Cardiology. 2021;17(3):7–34 (In Russ.). END LSQTKP.
Review
For citations:
Dausheva A.Kh., Zarubina E.G., Bogdanova Yu.V. Genetic markers of endothelial dysfunction in chronic obstructive pulmonary disease. Pacific Medical Journal. 2024;(1):48-52. (In Russ.) https://doi.org/10.34215/1609-1175-2024-1-48-52
Views:
407
Email this article 